图源:图虫作者 | 张羽岐编辑| 温斯婷8月26日晚间,拥有PD-1/VEGF双抗依沃西(商品名:依达方)和PD-1/CTLA-4双抗卡度尼利(商品名:开坦尼)等多款商业化产品的港股创新药企康方生物(09926.HK)发布2025年上半年业绩。财报数据显示,今年上半年,康方生物总收入为14.12亿元,同比增长37.75%。其中,商业销售收入为14.02亿元,与去年同期相比增长49.20%,系核心...
Source Link图源:图虫作者 | 张羽岐编辑| 温斯婷8月26日晚间,拥有PD-1/VEGF双抗依沃西(商品名:依达方)和PD-1/CTLA-4双抗卡度尼利(商品名:开坦尼)等多款商业化产品的港股创新药企康方生物(09926.HK)发布2025年上半年业绩。财报数据显示,今年上半年,康方生物总收入为14.12亿元,同比增长37.75%。其中,商业销售收入为14.02亿元,与去年同期相比增长49.20%,系核心...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.